Pratt Collard Advisory Partners LLC Has $519,000 Holdings in Becton Dickinson and Co (BDX)

Pratt Collard Advisory Partners LLC raised its position in Becton Dickinson and Co (NYSE:BDX) by 5.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,078 shares of the medical instruments supplier’s stock after buying an additional 100 shares during the period. Pratt Collard Advisory Partners LLC’s holdings in Becton Dickinson and were worth $519,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after buying an additional 283,433 shares during the last quarter. Vanguard Group Inc grew its position in shares of Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the period. BlackRock Inc. grew its position in shares of Becton Dickinson and by 1.9% during the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after acquiring an additional 355,223 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Becton Dickinson and by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock valued at $721,582,000 after acquiring an additional 223,215 shares during the period. Hedge funds and other institutional investors own 84.87% of the company’s stock.

A number of research firms have recently weighed in on BDX. Zacks Investment Research downgraded shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Tuesday. Barclays increased their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Monday. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Raymond James reduced their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research report on Tuesday, March 19th. Finally, TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $256.25.

In related news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Ribo Alberto Mas sold 4,808 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the completion of the transaction, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at $5,732,054.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is owned by insiders.

BDX opened at $240.02 on Wednesday. The company has a market capitalization of $64.58 billion, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $265.87. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. Becton Dickinson and’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period last year, the firm earned $2.48 EPS. On average, equities analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

ILLEGAL ACTIVITY WARNING: “Pratt Collard Advisory Partners LLC Has $519,000 Holdings in Becton Dickinson and Co (BDX)” was first reported by PressOracle and is the sole property of of PressOracle. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://pressoracle.com/news/2019/04/17/pratt-collard-advisory-partners-llc-has-519000-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Are FAANG stocks a good investment?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.